Development of PCR Assays for Detection of Trichomonas vaginalis in Urine Specimens

Centers for Disease Control and Prevention, Atlanta, GA, USA.
Journal of clinical microbiology (Impact Factor: 3.99). 02/2013; 51(4). DOI: 10.1128/JCM.03101-12
Source: PubMed


Trichomonas vaginalis infections are usually asymptomatic or can result in non-specific clinical symptoms, which makes laboratory-based detection of this protozoan parasite essential for diagnosis and treatment. We report the development of a battery of highly sensitive and specific PCR assays for detection of T. vaginalis in urine, a non-invasive specimen, and development of a protocol for differentiating among Trichomonas species that commonly infect humans.

Download full-text


Available from: Carolyn M Black, Oct 22, 2014
48 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Trichomonas vaginalis is the etiological agent of trichomoniasis, the most prevalent non-viral sexually transmitted disease worldwide. Trichomoniasis is a widespread, global health concern and occurring at an increasing rate. Infections of the female genital tract can cause a range of symptoms, including vaginitis and cervicitis, while infections in males are generally asymptomatic. The relatively mild symptoms, and lack of evidence for any serious sequelae, have historically led to this disease being under diagnosed, and under researched. However, growing evidence that T. vaginalis infection is associated with other disease states with high morbidity in both men and women has increased the efforts to diagnose and treat patients harboring this parasite. The pathology of trichomoniasis results from damage to the host epithelia, caused by a variety of processes during infection and recent work has highlighted the complex interactions between the parasite and host, commensal microbiome and accompanying symbionts. The commercial release of a number of nucleic acid amplification tests (NAATs) has added to the available diagnostic options. Immunoassay based Point of Care testing is currently available, and a recent initial evaluation of a NAAT Point of Care system has given promising results, which would enable testing and treatment in a single visit.
    Critical Reviews in Microbiology 11/2014; DOI:10.3109/1040841X.2014.958050 · 6.02 Impact Factor